The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Haywain / JHFH I think you are spot on... announcement of deals held back until conference to make the big splash. Would be pure fantasy to think that all the deals announced, converged coincidentally this week. Companies of all types rush out developments/products/initiatives with a deal in tow to help sell their wares at conferences/exhibitions. Unfortunately the PQ run was all Hemogenyx could announce through an RNS around that time and we have all seen how that impacted even though it was a positive step. He would have preferred and was trying to get CH sorted in time but it was not to be. At least it shows some business acumen in trying to combine progress with investors types. That's the least we should expect. We will get there, hare and tortoise and all that! GLA all & get well whoever needs to around this time. (PS: We are all hungry Hemogenyx, time for a banquet not a morsel).
Thailand are reporting a 300% increase in Zika cases. This is one of the CBR targets being tested. This virus has a devastating impact on unborn babies in terms of deformities and brain development. Hemogenyx, it would be good to get some sort of update on CBR soon. Even better, to be at the forefront of providing a solution to multiple viruses. GLA
Going to have to call in Claudia Winkleman, let her know there's another series taking place to establish who is faithful and who is a traitor. and has MrIndia been murdered? I know I'm a faithful !! GLA
It's not about telling the truth. It's about setting ambitious timescales.
Have you ever set a deadline date and come up short. It's not like we have had bad news. Next stage success will be a little later than desired that s all. It's potentially life-saving biotechnolgy not Deliveroo.
The time lag between the RNS detailing the successful completion of the 3rd PQ run on 23/1/23 and the analytical release test RNS announcement RNS on 23/3/23 -exactly 2 months.
The PQ re-run announced today already includes the announcement of successful completion of analytical release tests. Effectively both elements previously 2 months apart, announced today the same day. It looks likely then that the analytics put a drag on things rather than the PQ run. However better safe than sorry. I really don't yhink we are far from IND re-submission. The rational for saying that is it took just 47 days from RNS on analytics RNS to submit the whole IND application. There is so much less to do to meet the agreed FDA plan and they must be incredibly more versed in what to do and also have Prevail to help. In summary, I think we will see the IND re-submission well within January, with Clinical Hold comfortably within February. GLA
Mr Sandler is supported by other competent management people within Hemogenyx but unfortunately they choose not to, or indeed, dare not speak up on some of the glaring good business fundamentals that could be put in place to spread the word, rather than disenfranchise investors. It is hard to discern what some of them are doing in the absence of good communication. If institutional investors come on board that approach will have to change because they won't stand for it. The higher echelons within any business, not just CEO's, will then have to start pulling their weight if they are not doing so already. I am sure we will get there but does it have to be like walking through treacle all the time. I don't think so! GLA
The dilemma of what to do if the share price started travelling rapidly north on top of being in a shop trying to buy my wife a Christmas present is just too much. Will she like this, what size was it on the label, is it the right colour ....on top of that, no signal from the bowels of the shop I am caught in to enable me to trade if I needed to. So sod her!! .... (JUST JESTING) GLA
HT - still at it! For one with "truth" in your name, you should probably stick to it. You have never heard a Wednesday prediction from me, simply reference to it being only 2nd to Monday for key product related RNS's. However, not going to get entangled with you about it, but would like to see a more a positive focus toward Hemogenyx from you. Go on, come out that rut, you might enjoy it. Good luck to you and all!
HT I appreciate what you say and clearly there are differing views depending on where each person is on the time/performance curve, but surely we can focus on the upsides and get everyone's enthusiasm up a level. I do think that a flurry of good news from Dr Sandler is on the horizon. GLA
HT it was an after trading hours post yesterday so clearly wasn't a ramp as Mr I suggested earlier, neither was it a prediction. Wednesday has been a good day for announcements and is second only to Monday on the RNS product type RNS announcement, so yes, I had a good feeling about today. I am not devastated by the non-appearance of an RNS today and I will continue to have a good feeling about Wednesday relative to other days of the week excluding Monday's for "rough & ready" statistical reasons. If it landed today I certainly would not have been given investor guru status so on balance did not expected to be part of a run and commentary given that it has not arrived today. It will come when it comes and, unlike you, I certainly do not feel the need to drain every ounce of optimism from the positive and informed on LSE for the reasons outlined by JHFH today. So I suggest we both have a cup of tea and you finish your half-empty cup whilst I finish my half-full cup. Note we do have common ground, I am a shareholder and so are you. The actual difference is I am a willing one and you seem to be a constantly disgruntled one but, nevertheless, I wish all and you Sir, good luck. Now about next Wednes.............!!
Wednesday has been a good day in the past for getting RNS's. However, I've deliberately waited for close to say it, lest I be accused of something. If anyone wants more detailed statistical analysis, you can't have it! It's just a feeling I have in in my water, as the saying goes.
GLA
Looking at the number of shares traded Tuan6 is failing miserably in his objective, eloquently outlined by JHFH. It looks like everyone has a vice-like grip on their shares with more being inclined to buy than sell. My wife would have more success at getting shares from me if she really knew how deep I was in. Keep the faith. GLA
I think that when we get FDA approval, the SP will bounce even higher than initial expectations as those pulling out because of the Car T "concerns" suddenly appreciate they over thought the FDA/Car T concerns. There are ongoing concerns about any drug in its early life, Car T will be no different but it won't stop people being cured. There will also be plenty of CT candidates because time is running out for many and options for cures (even those with some risk) are limited. GLA
Johnnyr - Hemogenyx are in the business of science which I would contend would make a world of difference to some of the maxims of the Director you refer to. I am inclined to prefer a CEO aiming for 10 and getting 7 in contrast to someone aiming for a safe 5 and getting 5. With biotechnology requiring so much 3rd party involvement and FDA approval you either deliver a life saving therapy or not. There are no half-measures so you either achieve or f ail - no really any half measures. However, I accept you have a different view. GL
Within the RNS of 28/11/23 it specifically states:-
"Today's Placing will enable the Company to progress with its ambitious schedule to move forward to Clinical Trials..."
The company had an opportunity to readjust expectations that they would achieve FDA approval within 2023 as previously stated, but they did not. In fact, describing what they want to achieve as an "ambitious schedule" suggests to me they are still GOING FOR IT (IND approval) in 2023. They have a plan accepted by the FDA and undoubtedly some discussions ensued and they might already know that the turnaround from the FDA could be less than 30 days if they hit the required marker. Like some have said, it matters not if it appears in January to locked in investors but risky for those who think that the 30 days would be adhered to by the FDA. It would be nice to unwrap IND approval for Christmas!!! GLA